Abstract
Melphalan-based autologous stem cell transplant (Mel-ASCT) is a standard therapy for multiple myeloma, but is associated with severe oral mucositis (OM). To identify predictors for severe OM, we studied 381 consecutive newly diagnosed myeloma patients who received Mel-ASCT. Melphalan was given at 200 mg/m2 body surface area (BSA), reduced to 140 mg/m2 for serum creatinine > 3 mg/dl. Potential covariates included demographics, pre-transplant serum albumin and renal and liver function tests, and mg/kg melphalan dose received. The BSA dosing resulted in a wide range of melphalan doses given (2.4-6.2 mg/kg). OM developed in 75% of patients and was severe in 21%. Predictors of severe OM in multiple logistic regression analyses were high serum creatinine (odds ratio (OR = 1.581; 95% confidence interval (CI): 1.080-2.313; P = 0.018) and high mg/kg melphalan (OR = 1.595; 95% CI: 1.065-2.389; P = 0.023). An OM prediction model was developed based on these variables. We concluded that BSA dosing of melphalan results in wide variations in the mg/kg dose, and that patients with renal dysfunction who are scheduled to receive a high mg/kg melphalan dose have the greatest risk for severe OM following Mel-ASCT. Pharmacogenomic and pharmacokinetic studies are needed to better understand interpatient variability of melphalan exposure and toxicity.
Original language | English (US) |
---|---|
Pages (from-to) | 501-506 |
Number of pages | 6 |
Journal | Bone Marrow Transplantation |
Volume | 38 |
Issue number | 7 |
DOIs | |
State | Published - Oct 2006 |
ASJC Scopus subject areas
- Hematology
- Transplantation